Autologous Hematopoietic Stem Cell Transplantation Combined With CD19-CART Treatment of Adult High-risk Acute Lymphoblastic Leukemia

Launched by INSTITUTE OF HEMATOLOGY & BLOOD DISEASES HOSPITAL, CHINA · Sep 19, 2024

Keywords

ClinConnect Summary

This clinical trial is studying a new treatment approach for adults with high-risk acute lymphoblastic leukemia (ALL), a type of blood cancer. The treatment combines two methods: a procedure called autologous hematopoietic stem cell transplantation, where a patient's own stem cells are used, and a special type of therapy known as CD19-CAR-T, which helps the immune system fight cancer. The goal is to see how effective this combined treatment is and to monitor any side effects that participants might experience.

To be eligible for this trial, patients must be adults who have achieved complete remission after initial chemotherapy and are ready for stem cell transplantation. They should not have serious infections or other significant health issues, and they cannot have other types of cancer. Participants can expect close medical supervision throughout the study, which is currently recruiting volunteers. This trial aims to improve treatment options for individuals facing this challenging condition.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Adult patients with high-risk acute B-lymphoblastic leukemia
• • Complete remission was achieved after induction chemotherapy, and autologous CD19-CAR-T was successfully prepared
• • Eligible for autologous hematopoietic stem cell transplantation
• • No major organ dysfunction
• Exclusion Criteria:
• • Combined with malignant tumors of other organs
• • With a serious infection that is not under control
• • Syphilis, AIDS, hepatitis B, hepatitis C, any one of them positive
• • Patients who have had an allergic reaction to the drugs used in this study or similar drugs
• • Other patients deemed unsuitable for inclusion by the investigators